

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 311/80, 311/92, A61K 31/35	A2	(11) International Publication Number: WO 99/57107 (43) International Publication Date: 11 November 1999 (11.11.99)
(21) International Application Number: PCT/US99/09806 (22) International Filing Date: 4 May 1999 (04.05.99) (30) Priority Data: 60/084,129 4 May 1998 (04.05.98) US (71) Applicant: THE UNIVERSITY OF CONNECTICUT [US/US]; 263 Farmington Avenue, Farmington, CT 06030 (US). (72) Inventors: MAKRIYANNIS, Alexandros; 348G Foster Drive, Willimantic, CT 06226 (US). KHANOLKAR, Atmaram; No. 55, 1 South Eagleville Road, Storrs, CT 06268 (US). LU, Dai; No. 16, 1 South Eagleville Road, Storrs, CT 06268 (US). (74) Agents: CARROLL, Alice, O. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i> <div style="text-align: right;">24 24 — 48</div>
(54) Title: CANNABINOIDS SELECTIVE FOR THE CB2 RECEPTOR (57) Abstract Disclosed are novel cannabinoids which are selective for the CB2 receptor. The novel cannabinoids comprise a substituted or unsubstituted tricyclic cannabinoid core and a substituted or unsubstituted C5-C8 carbocyclic ring, five to eight-membered heterocyclic ring or a seven to ten membered bicyclic ring system fused to the monohydroxylated phenyl ring of the cannabinoid core. Also disclosed are methods of suppressing the immune system in a subject by administering to the subject a (e.g. immunosuppressive amount) effective amount of a novel cannabinoid described above.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakistan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

CANNABINOIDS SELECTIVE FOR THE CB2 RECEPTOR

BACKGROUND OF THE INVENTION

Δ^8 -Tetrahydrocannabinol, the psychoactive marijuana derived cannabinoid, binds to the CB1 receptor in the brain and to the CB2 receptor in the spleen. Activation of the CB2 receptor has been shown to result in suppression of the immune system (Mechoulam, *Cannabinoids as Therapeutic Agents*, CRC Press, Boca Raton, FL (1986)). Thus, drugs which selectively activate the CB2 receptor have great potential as immunomodulatory agents for preventing tissue rejection in organ transplant patients and as immunosuppressive agents for treating autoimmune associated diseases, (e.g., lupus erythematosus, rheumatoid arthritis, psoriasis, multiple sclerosis and inflammatory bowel diseases such as ulcerative colitis and Crohn's disease). CB2 receptor agonists also can be used as anti-inflammatory agents and as agents for suppressing peripheral and idiopathic pain.

Unfortunately, most known CB2 receptor agonists, including most cannabinoids, are non-selective in that they also stimulate the CB1 receptor. Activation of the


-2-

CB1 receptor causes the sedative and psychotropic effects which are associated with marijuana use. As a consequence, there are few if any agents which can target the CB2 receptor without at the same time causing these undesirable side-effects. The full potential of therapies which modulate the immune system by selectively stimulating the CB2 receptor is unlikely to be realized without the further development of agents which are selective agonists of the CB2 receptor.

10


SUMMARY OF THE INVENTION

Reported herein are novel compounds which selectively activate the CB2 receptor. These compounds are cannabinoids in which the alkyl side chain typically found in cannabinoids has been replaced with a monocyclic or bicyclic ring that is fused to the tricyclic core typically found in cannabinoids. For example, the affinity of AM724 for the CB2 receptor was found to be about 400 times greater than for the CB1 receptor (Example 2). The structure of AM724 is shown below along with Δ^8 -tetrahydrocannabinol.



AM724

-3-



Delta-8-Tetrahydrocannabinol

Based on these results, novel compounds which are selective CB2 receptor agonists and the use of these compounds for modulating the immune system in a subject are disclosed.

One embodiment of the present invention is a compound comprising a substituted or unsubstituted tricyclic cannabinoid core. The cannabinoid core comprises a phenyl ring and a six-membered carbocyclic ring fused to a central pyran ring or to a central six-membered lactone ring (preferably a pyran ring). A substituted or unsubstituted C5-C8 carbocyclic ring, a five to eight-membered heterocyclic ring or a seven to ten membered bicyclic ring is fused to the phenyl ring. Also included are physiologically acceptable salts of the compound.

Another embodiment of the present invention is a method of suppressing the immune system in a subject. The method comprises administering to the subject a therapeutically effective amount of a compound

-4-

comprising a substituted or unsubstituted tricyclic cannabinoid core. The cannabinoid core comprises a phenyl ring and a six-membered carbocyclic ring fused to a central pyran ring or to a central six-membered lactone ring (preferably a pyran ring). A substituted or unsubstituted C5-C8 carbocyclic ring, a five to eight-membered heterocyclic ring or a seven to ten membered bicyclic ring is fused to the phenyl ring. The compounds of the present invention are effective in stimulating the CB2 receptor without substantially activating the CB1 receptor. Thus, the compounds of the present invention can suppress the immune system in subjects without causing the psychotropic and sedative side-effects which are characteristic of cannabinoids such as Δ^8 -tetrahydrocannabinol. These compounds are therefore useful as drugs for suppressing organ transplant rejection, for treating autoimmune diseases (e.g., lupus erythematosus, rheumatoid arthritis, psoriasis, multiple sclerosis and inflammatory bowel disease such as ulcerative colitis and Crohn's disease), for treating inflammation, and for suppressing peripheral and idiopathic pain. In addition, the compounds of the present invention are likely to cause no more than minimal side-effects.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the structure of a number of the novel compounds of the present invention.

Figure 2 is a schematic showing two synthesis of (-)- Δ^8 -tetrahydrocannabinol and cannabinol analogs with cyclic side chains.

-5-

Figure 3 is a schematic showing two synthesis of (-)- Δ^8 -tetrahydrocannabinol and cannabinol analogs with a bridged bicyclic side chains.

Figure 4 is a schematic showing a synthesis of (-)- Δ^8 -tetrahydrocannabinol and cannabinol analogs with substituted cyclic side chains.


Figures 5A, 5B and 5C show the structure of a number of the novel compounds of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

10 Cannabinoids have a core tricyclic ring system in which a phenyl ring and a six membered ring are each fused to a central pyran ring or to a six-membered lactone ring (preferably a pyran ring). In addition, cannabinoids are able to induce characteristic
15 physiological effects in mammals, including euphoria, delerium, drowsiness, hallucinations, weakness and/or hyporeflexia. The tricyclic core found in some cannabinoids is shown in Structural Formula (I). Other cannabinoids have the tricyclic core shown in Structural
20 Formula (I), modified to include one or more double bonds in Ring A, for example, a double bond between carbons 8 and 9, between carbons 9 and 10 or between carbons 9 and 11. Yet other cannabinoids have the core structures described above, modified to include
25 hydrogen, hydroxyl, hydroxymethyl, halogen (chloro, bromo, iodo and fluoro), methoxy, ethoxy, nitrile, nitro, halogenated methyl, halogenated ethyl, methoxymethyl, ethoxymethyl, nitromethyl, ethyl or $-\text{CH}_2\text{CN}$ group bonded to carbon 11 instead of a methyl group. In
30 other cannabinoids, the hydroxyl group at position 1 of the core structure is replaced, for example, with $-\text{H}$,

-6-

-OCH₃, -NH₂ or -NHCH₃. The term "tricyclic cannabinoid core", as it is used herein, also refers to structures which are 1) related to Structural Formula (I); and (2) found in compounds which induce one or more of the
 5 physiological effects described above that are characteristic of the cannabinoids. Also shown in Structural Formula (I) is a numbering system for the ring atoms in the core tricyclic structure.



10

(I)

Cannabinoids also generally substituted with a linear alkyl side chain at position C-3 of the cannabinoid core. In the cannabinoids of the present
 15 invention, the linear alkyl side chain is replaced with a substituted or unsubstituted C5-C8 carbocyclic ring, a

-7-

five to eight-membered heterocyclic ring or a seven to ten membered bicyclic ring fused to positions two and three of the cannabinoid core.

Suitable substituents for a tricyclic cannabinoid core include groups which do not significantly diminish the ability of a cannabinoid to activate a cannabinoid receptor. Substitutions can occur at positions 2, 4, 6a-10a or at the three methyl groups. Substitution(s) at more than one position are possible. Substituents which do not significantly diminish the biological activity of cannabinoids are generally small, pharmacophoric groups. Examples include -H, -OH, -OCH₃, -OCH₂CH₃, halogen (e.g., chloro, bromo, iodo and fluoro), -CN, azido, isocyanate, isothiocyanate, -NO₂, -CH₃, -C(halogen)₃, -CH₂OH, -CH₂OCH₃, -CH₂OCH₂CH₃, -CH₂(halogen), -CH₂CN, -CH₂NO₂, -CH₂CH₃ and -CH₂C(halogen)₃. Cannabinoids with other substituents can be prepared by modification of the synthetic procedures described in Example 1 and shown in Figures 2-4. For example, replacing the alcohol which reacts with compound 4 in Scheme 1 of Figure 2 with a suitably substituted analog results in the preparation of cannabinoids with a substituted cyclohexene ring or with substituents on one of the methyl groups attached to the pyran or cyclohexene ring. Other suitable substituents can be identified by testing modified cannabinoids in the *in vitro* CB1 or CB2 assays described in Example 2.

Two rings are fused when they share one single bond, one double bond or two adjacent ring atoms. For example, a cyclohexane ring fused to a phenyl ring forms a tetrahydronaphthalene group; a cyclopentane ring fused to a phenyl ring forms an indane group. In the present

-8-


invention, the phenyl ring of the cannabinoid core is fused to a substituted or unsubstituted C5-C8 carbocyclic, a C5-C8 non-aromatic heterocyclic ring or to a seven to ten membered bicyclic ring.

5 Carbocyclic rings are non-aromatic rings which include only carbon as ring atoms. Examples include substituted or unsubstituted cyclopentane, cyclohexane, cycloheptane and cyclooctane.


Heterocyclic rings are non-aromatic rings which
10 have one or more heteroatoms, including oxygen, nitrogen and/or sulfur, as ring atoms. Examples of suitable heterocyclic rings include substituted or unsubstituted tetrahydrofuran, tetrahyrothiophene, 1,4-dioxane, morpholine, thiomorpholine, pyrrolidine, pyran,
15 piperazine, piperidine and thiazolidine.

Bicyclic ring systems contain two non-aromatic rings which are bridged or fused. Optionally, a bicyclic ring can have one or more heteroatoms such as oxygen, sulfur or nitrogen. An example of a suitable
20 fused ring system is decalin. Bridged bicyclic rings share at least three ring atoms and therefore also share at least two single bonds or one single bond and one double bond. Examples of bicyclic structures include a 2.2.1 seven-membered bicyclic structure, a 3.2.1 eight-
25 membered bicyclic structure, a 3.3.1 nine-membered bicyclic structure, a 2.2.2 eight-membered structure and a 3.3.2 nine-membered structure. The structures of carbocyclic 2.2.1 seven membered, a 3.2.1 eight-membered bicyclic, a 3.3.1 nine-membered bicyclic, a 2.2.2 eight-
30 membered and a 3.3.2 nine-membered ring are provided by Structural Formulas (II) - (VI):


-9-




(II)




(III)



(IV)



(V)



(VI)


5 The nomenclature for bicyclic ring systems indicates the number of rings atoms between bridgeheads. A "bridgehead" is an atom shared by both rings. For example, bicyclo 2.2.1. heptane, shown in Structural Formula (II), has two (C-2 and C-3), two (C-5 and C-6) and one (C-7) carbons between the bridgeheads (C-1 and C-4)

Suitable substituents for the fused carbocyclic, heterocyclic rings and bicyclic ring systems are generally C1-C8 alkyl groups, C1-C8 substituted alkyl groups or small, pharmacophoric groups. Examples of small pharmacophoric groups include, but are not limited to, -H, -OH, -OCH₃, -OCH₂CH₃, halogen (e.g., chloro,

-10-

bromo, iodo and fluoro), -CN, azido, isocyanate, thioisocyanate, -NO₂, -CH₃, -C(halogen)₃, or -CH₂OH, -CH₂OCH₃, -CH₂OCH₂CH₃, -CH₂(halogen), -CH₂CN, -CH₂NO₂, -CH₂CH₃ and -CH₂C(halogen)₃. Alkyl groups can be straight chained
5 or branched. Suitable substituents for an alkyl group include small, pharmacophoric groups, as described above.

In a preferred embodiment, the selective CB₂ agonist of the present invention is represented by
10 Formula (VII):



(VII)

Ring A has zero, one or two endocyclic double bonds. An "endocyclic double bond" is defined to be a double bond
15 formed between two carbon atoms in a ring. In one example, Ring A has three double bonds. In another example, Ring A has a double bond between carbons 8 and 9. In another example, Ring A has a double bond between carbons 9 and 10. In yet another example, Ring A has no
20 double bonds.

-11-


X is $>\text{C}(\text{CH}_3)_2$ or $-\text{C}=\text{O}$. X is preferably $>\text{C}(\text{CH}_3)_2$.

R_1 is $-\text{H}$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_3$, halogen (chloro, bromo, iodo and fluoro), $-\text{CN}$, $-\text{NO}_2$, $-\text{CH}_3$, $-\text{C}(\text{halogen})_3$, $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{OCH}_2\text{CH}_3$, $-\text{CH}_2(\text{halogen})$, $-\text{CH}_2\text{CN}$,
 5 $-\text{CH}_2\text{NO}_2$, $-\text{CH}_2\text{CH}_3$ or $-\text{CH}_2\text{C}(\text{halogen})_3$. R_1 in Structural Formula (VII) is preferably $-\text{H}$ or $-\text{OH}$.

R_2 and R_3 , taken together with the carbon atoms to which they are bonded, form a substituted or unsubstituted C5-C8 monocyclic or C7-C10 bicyclic
 10 carbocyclic ring.

In a more preferred embodiment, the selective CB2 agonist of the present invention is represented by Formula (VIII):

15



(VIII)


R_1 is $-\text{CH}_3$ or $-\text{CH}_2\text{OH}$.

-12-

R_4 - R_7 are independently -H or a C1 to C10 straight chained substituted or unsubstituted alkyl group. R_4 and R_5 are preferably -H or -CH₃.

In addition, R_6 and R_7 , taken together, form a substituted or unsubstituted alkylene group, for example, an ethylene, propylene or -(CH₂)₄- group. Suitable substituents for an alkylene group are as described for a carbocyclic or bicyclic ring.

In an even more preferred embodiment, the selective
10 CB2 agonist of the present invention is represented by Formula (IX):



(IX)

15 R_1 , R_4 and R_5 are as described for Structural Formula (VIII). R_8 is a substituted or unsubstituted C1-C4 alkyl group, preferably a methyl group.

-13-

Specific examples of the compounds of the present invention are shown in Figures 1 and 5.

In another preferred embodiment, the selective CB2 agonist of the present invention is represented by
5 Formula (VII); (VIII) or (IX), modified so that the hydroxyl group attached to the phenyl ring is replaced with an -H.

A "therapeutically effective amount" is the quantity of compound which results in immune system
10 suppression in a subject after administration of the compound. Typically, a "therapeutically effective amount" of the compound ranges from about 10 mg/day to about 1000 mg/day, preferably from about 50 mg/day to about 500 mg/day. The specific dosage level of active
15 ingredient will depend upon a number of factors, including, for example, biological activity of the particular preparation, age, body weight, sex and general health of the subject being treated.

As used herein, a "subject" refers to a human or
20 animal. An "animal" refers to veterinary animals, such as dogs, cats, horses, and the like, and farm animals, such as cows, pigs, guinea pigs and the like.

The compounds of the present invention can be administered by a variety of known methods, including
25 orally, rectally, or by parenteral routes (e.g., intramuscular, intravenous, subcutaneous, nasal or topical). The form in which the compounds are administered will be determined by the route of administration. Such forms include, but are not limited
30 to capsular and tablet formulations (for oral and rectal administration), liquid formulations (for oral, intravenous, intramuscular or subcutaneous

-14-

administration) and slow releasing microcarriers (for rectal, intramuscular or intravenous administration). The formulations can also contain a physiologically acceptable vehicle and optional adjuvants, flavorings, colorants and preservatives. Suitable physiologically acceptable vehicles may include saline, sterile water, Ringer's solution, and isotonic sodium chloride solutions.

The compounds of the present invention can be prepared according to synthetic methods shown in Figures 2-4. Exemplary conditions for these syntheses are provided in Example 1. Deoxy analogs, i.e., compounds in which the hydroxyl group attached to the phenyl ring is replaced by -H, can be prepared by suitable modification of these procedures. For example, deoxy compounds can be prepared by using the appropriate dimethoxy analog in place of compound 1 in the schemes shown in Figure 2 or a monomethyl recorcinol in place of 2,6-dimethoxyphenol in the schemes shown in Figure 3.

Also included in the present invention are physiologically acceptable salts of the novel CB2 selective agonists disclosed herein. Salts of compounds containing a phenolic group or other acidic functional group can be prepared by reacting with a suitable base, for example, a hydroxide base or amine base. Salts of acidic functional groups contain a counteranion such as sodium, potassium, ammonium and the like. Salts of compounds containing an amine or other basic group can be obtained, for example, by reacting with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like. Compounds with a quaternary ammonium group also

-15-

contain a counteranion such as choride, bromide, iodide, acetate, perchlorate and the like.

The novel compounds of the present invention have utilities other than immunomodulation. For example, the

5 CB2 selective cannabinoids disclosed herein can be used to screen cells for CB2 receptor expression. The cells are contacted with a radiolabelled CB2 selective cannabinoid, washed to remove unbound compound and then counted to assess retained radioactivity. Cells which

10 retain radioactivity bind the CB2 selective cannabinoids and are therefor likely to express the CB2 receptor. CB2 selective cannabinoids can also be used to identify other compounds which bind to the CB2 receptor. For example, radiolabelled CB2 selective cannabinoids can be

15 used in place of CP-55,940 in the CB2 assay described in Example 2. Radiolabeled cannabinoids can be prepared by, for example, by using tritiated reducing agents in converting compound 7 in Figure 2 to compound 8.

The invention is illustrated by the following

20 examples which are not intended to be limiting in any way.

EXEMPLIFICATION

Example 1 - Preparation of the compound of the present invention

25 Compound 2. A solution of 1.8 g (7.63 mmol) of the known tetralone 1 in 15 mL of dry THF was cooled in an ice-bath and freshly prepared solution of n-hexylmagnesium bromide (9.20 mmol) was added dropwise.

-16-

The resulting mixture was stirred at room temperature overnight and then poured into saturated ammonium chloride solution. The product was extracted in diethyl ether, organic extracts were combined, dried and
5 solvents removed by rotary evaporation. The crude product was dissolved in 30 mL of chloroform. About 10 mg of p-toluenesulfonic acid was added and the resulting mixture was stirred at room temperature for 30 min. The reaction mixture was washed with 10% sodium bicarbonate
10 solution, dried, and the chloroform evaporated. The residue was chromatographed on silica gel (10% ethyl ether-petroleum ether) to afford 1.90 g (82%) of pure 2 as a colorless oil.

Compound 3. 1.20 g (3.95 mmol) of the alkene 2 was
15 dissolved in 40 mL of absolute ethanol, 200 mg of 10% Pd on C catalyst was added and the solution was subjected to hydrogenation at room temperature and atmospheric pressure for 2 h. The catalyst was filtered off and the filtrate was rotary evaporated. The residue was
20 purified on a small silica gel column to afford 1.11 g (92%) of compound 3.

Compound 4. A piece of potassium metal 105.5 mg (2.70 mmol) in 4 mL of dry THF was heated to reflux with vigorous stirring and then cooled quickly in an ice
25 bath. To this potassium sand, a solution of 0.7 g (2.29 mmol) of compound 3 in 1 mL of THF was added in one portion under a blanket of argon. The red-color mixture was stirred at room temperature for 24 h and then terminated by addition of small amount of methanol

-17-

followed by water. After acidification, the reaction mixture was extracted with diethyl ether. Combined ether extracts were dried and ether evaporated to afford an oil which was chromatographed to give 260 mg (45%) of the pure product.

A solution of the above dimethyl ether (250 mg, 0.9 mmol) in dichloromethane was cooled in ice bath under argon and 1.26 mL of a 1 M solution of boron tribromide (2.26 mmol of BBr₃) in dichloromethane was added dropwise. The reaction mixture was stirred at room temperature for 2 h and then quenched by cautious addition of water. The organic layer was separated, washed with 10% sodium bicarbonate and dried. Rotary evaporation gave a crude product which was chromatographed on silica gel (50% ethyl ether-petroleum ether) to afford 190 mg (85%) of resorcinol 4.

Compound 5 & 6. 7 mg of p-toluenesulfonic acid was added to the solution of resorcinol 4 (63.3 mg, 0.25 mmol) and 43.6 mg of cis/trans-p-menthediene (0.28 mmol) in 2.5 mL of chloroform, and the mixture was refluxed for 45 min. The solution was cooled to room temperature, washed with 10% sodium bicarbonate, dried, and evaporated. The residue was chromatographed on silica gel (7% ethyl ether-petroleum ether) to afford 35 mg of tetrahydrocannabinol 5 and 7 mg of tetrahydrocannabinol 6 (combined yield 63%).

Compound 7. A solution of potassium bis(trimethylsilyl)amide (2.03 mmol in 5 mL of dry THF) was cooled to -78 °C under argon and a solution of 0.4 g of compound 1 (1.69 mmol) in 1 mL of dry THF was added

-18-

dropwise. The solution was stirred at 78 °C for 45 min and 0.25 mL of 1-bromopentane (neat) was added. The reaction mixture was allowed to warm slowly to room temperature and stirred overnight. The mixture was
5 poured into saturated ammonium chloride solution and extracted with diethyl ether. Combined ether extracts were dried and ether removed. The residue was chromatographed on silica gel (30% ethyl ether-petroleum ether) to afford 0.38 g (75%) of the alkylated product.

10 Compound 8.

Hydrogenolysis of 7. A solution of 70 mg (0.23 mmol) of 7 in 2.3 mL of absolute ethanol was mixed with 11.5 mg of 10% Pd on C catalyst. A few drops of concentrated hydrochloric acid was added and the mixture was
15 hydrogenated at room temperature and atmospheric pressure for 6 h. At the end of the time period, catalyst was filtered off and ethanol was removed by rotary evaporation. The residue was passed through a short column of silica to afford 63.8 mg (90%) of the
20 desired product.

Demethoxylation. The procedure used is identical to the one described above for the preparation of compound 4. Thus, starting from 370 mg (1.27 mmol) of the trimethoxy compound, 106 mg (43%) of the corresponding dimethoxy
25 compound was obtained.

Demethylation using boron tribromide. Procedure similar to the one described for the preparation of compound 4. Starting from 100 mg (0.38 mmol) of the dimethyl ether, 76.5 mg (86%) of resorcinol 8 was obtained.

-19-

Compound 9. Procedure used is similar to the one described for the preparation of compound 5. Starting from 61.6 mg (0.26 mmol) of the resorcinol 8, 59.2 mg (62%) of tetrahydrocannabinol 9 was obtained.

- 5 Compound 10. The mixture of 6.50 g of 2,5-dimethoxy phenol (42 mmol) and 7.70 g of (1S, 2S, 3S, 5R)-(+) - isopinocampheol (50 mmol) in 200 ml of 70% methanesulfonic acid was heated and stirred in a 70 °C oil bath for 24 hr. After cooling to room temperature,
10 the reaction mixture was poured onto ice and extracted with methylene chloride. The extracts were washed with water and saturated with sodium bicarbonate solution, dried with sodium sulfate. Removal of solvent provided 15.0 g of brown oil crude. The crude was subjective to
15 multiple column chromatography purification with the elution solvent of the mixture of hexane, methylene chloride and ethyl acetate (5: 5: 1). The component of Rf value of 0.52 was collected.

Compounds 11 to 13

- 20 These three compounds were prepared by the methods described in Dominiami et al., *J. Org. Chem.* 42:344 (1977), the entire teachings of which are incorporated herein by reference.

Compounds 14 and 15

- 25 The mixture of 1 mmol of 13, 3 mmol trans-p-mentha-2, 8-dien-1-ol and 36 mg of p-toluenesulfonic acid monohydrate in 10 ml of chloroform was stirred and heated in a 70°C oil bath for 3 hours. Then the reaction temperature was lowered to room temperature.

-20-

The reaction was quenched by addition of 5 ml of saturated sodium bicarbonate solution. After separation, the aqueous layer was extracted twice by methylene chloride. The combined organic layer is washed by brine, dried over sodium sulfate. Removal of solvent by vacuum evaporation provided the yellow oil crude product. The products were purified by column chromatography. Elution solvent was the mixture of petroleum ether and ethyl acetate with the ratio of 100 to 3. The yield of 14 was 28%. The yield of 15 was 30%. The melting point of 14 was 72-73°C. The melting point of 15 was 216-217°C.

Compounds in Scheme 4 of Figure 4.

The compounds in scheme 4 of Figure 4 are synthesized through the methods described in Love et al., *J. Med. Chem.* 16:1200 (1973), Meltzer et al., *Synthesis*, 1981:985 (1981) and Gareau, *Bioorg. Med. Chem. et al.*, 6:189 (1996), the entire teachings of which are incorporated herein by reference.

Example 2 - Compounds of the present invention selectively bind to the CB2 receptor

RADIOLIGAND BINDING ASSAY

The binding affinities of the novel compounds described in this invention for the central cannabinoid receptor were assessed using rat forebrain membranes as a source of CB1. Membranes were prepared as described by the method of Dodd et al., *Brain Res.* 226:107 (1981), the entire teachings of which are incorporated herein by reference. Rat whole brains minus the cerebral cortex

-21-

were diced with a razor blade and homogenized in 0.32 M sucrose, pH 7.4. The resulting suspension was spun at 400 x g at 4°C. The supernatant was decanted and layered over 1.2 M sucrose in TME buffer (25 mM Tris base, 5 mM MgCl₂, 1 mM EDTA, pH 7.4) and spun at 109,000 x g. The interface containing plasma membrane protein was collected, pooled and layered over 0.8 M sucrose in TME, pH 7.4. The pellet was carefully resuspended in TME, pH 7.4 and the total protein content was assayed by the method of Markwell et al., *Anal. Biochem.* 87:206 (1978), the entire teachings of which are incorporated herein by reference. Protein was aliquotted, frozen under liquid nitrogen and stored at -80°C until use.

Approximately 30 µg of tissue was incubated in silanized 96 well microtiter plate with TME containing 0.1% essentially fatty acid free bovine serum albumin (BSA), 0.8 nM [³H]CP-55,940 and various concentrations of the test compound in a final volume of 200 µL. Assays were incubated at 30°C for 1 hour. The samples were filtered using Packard Filtermate 196 and Whatman GF/C Filterplates and washed with wash buffer (TME) containing 0.5% BSA. Radioactivity was detected using MicroScint 20 scintillation cocktail added directly to the dried filterplates, and the filterplates were counted using a Packard Instruments Top-Count. Nonspecific binding was assessed using 100 nM CP-55,940. Data collected from three independent experiments performed with duplicate determinations were normalized between 100% and 0% specific binding for [³H]CP-55,940, determined using buffer and 100 nM CP-55,940. The normalized data was analyzed using a 4 parameter

-22-

nonlinear logistic equation to yield IC_{50} values. Data from at least two independent experiments performed in duplicate were used to calculate IC_{50} values which were converted to K_i values using the assumptions of Cheng and
5 Prusoff, *Biochem. Pharmacol.* 22:3099 (1973), the entire teachings of which are incorporated by reference.

Mouse spleen was used as a source of CB2 receptors to assess binding affinity of analogs described in this invention. The CB2 binding assay was conducted in the
10 same manner as for CB1. Silanized centrifuge tubes were used throughout to minimize receptor loss due to adsorption.

The K_i s (nanomolar) for a number of the compounds of the present invention are shown in the Table below:

15 Table

Compound	K_i in nM for the CB1 Receptor	K_i in nM for the CB2 Receptor
AM724	6877	16.9
AM725	3.6×10^5	280.5
AM726	2018	83.2
20 AM727	6.2×10^4	1244
AM856	402.4	161.5
AM855	22.3	58.6
AM858	524.1	455.6

As can be seen, a number of compounds have an affinity
25 for the CB2 receptor that is several orders of magnitude greater than for the CB1 receptor.

-23-


While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made
5 therein without departing from the spirit and scope of the invention as defined by the appended claims.

-24-

CLAIMS

What is claimed is:

1. A compound comprising a tricyclic cannabinoid core and a substituted or unsubstituted C5-C8 carbocyclic ring, a five to eight-membered heterocyclic ring or a seven to ten membered bicyclic ring system, wherein:
- a) the tricyclic cannabinoid core comprises a phenyl ring and a six-membered carbocyclic ring fused to a central pyran ring or to a central six-membered lactone ring; and
- b) the substituted or unsubstituted C5-C8 carbocyclic ring, five to eight-membered heterocyclic ring or a seven to ten membered bicyclic ring system is fused to the phenyl ring,
- and physiologically acceptable salts thereof.
2. The compound of Claim 1 wherein the compound is represented by the following structural formula:



-25-

wherein Ring A has zero to three endocyclic double bonds;


X is $>\text{C}(\text{CH}_3)_2$ or $-\text{C}=\text{O}$;

5 R_1 is $-\text{H}$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_3$, halogen, $-\text{CN}$, $-\text{NO}_2$, $-\text{CH}_3$, $-\text{C}(\text{halogen})_3$, $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{OCH}_2\text{CH}_3$, $-\text{CH}_2(\text{halogen})$, $-\text{CH}_2\text{CN}$, $-\text{CH}_2\text{NO}_2$, $-\text{CH}_2\text{CH}_3$ or $-\text{CH}_2\text{C}(\text{halogen})_3$; and

10 R_2 and R_3 , taken together with the carbon atoms to which they are bonded, form a substituted or unsubstituted C5-C7 monocyclic or a C7-C10 bicyclic carbocyclic ring.

3. The compound of Claim 2 wherein the compound is represented by the following structural formula:

15



wherein:

R_1 is $-\text{CH}_3$ or $-\text{CH}_2\text{OH}$;


-26-

R_4 - R_7 are independently -H or a C1 to C10 straight chained substituted or unsubstituted alkyl group; and

5 wherein R_6 and R_7 , taken together, form a substituted or unsubstituted ethylene, propylene or $-(CH_2)_4$ - group.

4. The compound of Claim 3 wherein R_4 and R_5 are -H or $-CH_3$.


10 5. The compound of Claim 4 wherein the compound is represented by the following structural formula:




15 wherein R_8 is a C1-C4 substituted or unsubstituted alkyl group.

6. The compound of Claim 5 wherein the compound is represented by a structural formula selected from:

-27-



or




7. A method of suppressing the immune system in a subject comprising administering to the subject a therapeutically effective amount of a compound

-28-

comprising a tricyclic cannabinoid core and a substituted or unsubstituted C5-C8 carbocyclic ring, a five to eight-membered heterocyclic ring or a seven to ten membered bicyclic ring system, wherein:

- 5
- a) wherein the tricyclic cannabinoid core comprises a phenyl ring and a six-membered carbocyclic ring fused to a central pyran ring or a central six-membered lactone ring; and
- 10 b) the substituted or unsubstituted C5-C8 carbocyclic ring, five to eight-membered heterocyclic ring or a seven to ten membered bicyclic ring system is fused to the phenyl ring
- 15 and physiologically acceptable salts thereof.

8. The method of Claim 7 wherein the compound is represented by the following structural formula:



20 wherein Ring A has zero to three endocyclic double bonds;


-29-

X is $>\text{C}(\text{CH}_3)_2$ or $-\text{C}=\text{O}$;

R_1 is $-\text{H}$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_3$, halogen, $-\text{CN}$,
 $-\text{NO}_2$, $-\text{CH}_3$, $-\text{C}(\text{halogen})_3$, $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{OCH}_3$,
 $-\text{CH}_2\text{OCH}_2\text{CH}_3$, $-\text{CH}_2(\text{halogen})$, $-\text{CH}_2\text{CN}$, $-\text{CH}_2\text{NO}_2$, $-\text{CH}_2\text{CH}_3$ or
 $-\text{CH}_2\text{C}(\text{halogen})_3$; and

R_2 and R_3 , taken together, form a substituted
 or unsubstituted C5-C7 monocyclic or C7-C10
 bicyclic carbocyclic ring.

9. The method of Claim 8 wherein the compound is
 10 represented by the following structural formula:



wherein:


R_1 is $-\text{CH}_3$ or $-\text{CH}_2\text{OH}$;

- R_4 - R_7 are independently $-\text{H}$ or a C1 to C10
 15 straight chained substituted or unsubstituted alkyl
 group; and

-30-

wherein R_6 and R_7 , taken together, can form a substituted or unsubstituted ethylene, propylene or $-(CH_2)_4-$ group.

10. The method of Claim 9 wherein R_4 and R_5
5 independently are $-H$ or $-CH_3$.
11. The method of Claim 10 wherein the compound is represented by the following structural formula:




10


wherein R_8 is a C1-C4 substituted or unsubstituted alkyl group.

12. The method of Claim 11 wherein the compound is represented by a structural formula selected from:

-31-



or




13. A substituted or unsubstituted cannabinoid having a side chain comprising a substituted or unsubstituted C5-C8 carbocyclic ring, a five to


-32-

eight-membered heterocyclic ring or a seven to ten membered bicyclic ring fused to carbons two and three of the cannabinoid.


1/7




AM724




AM725



AM856




AM855



AM858

FIGURE 1

Scheme 1



Scheme 2




FIGURE 2

3/7

Scheme 3




Figure 3

Scheme 4




Figure 4

5/7




FIGURE 5A





FIGURE 5B

7/7



R = -CH₃ or -CH₂OH

FIGURE 5C

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 311/80, 311/92, A61K 31/35	A3	(11) International Publication Number: WO 99/57107 (43) International Publication Date: 11 November 1999 (11.11.99)
(21) International Application Number: PCT/US99/09806 (22) International Filing Date: 4 May 1999 (04.05.99) (30) Priority Data: 60/084,129 4 May 1998 (04.05.98) US (71) Applicant: THE UNIVERSITY OF CONNECTICUT [US/US]; 263 Farmington Avenue, Farmington, CT 06030 (US). (72) Inventors: MAKRIYANNIS, Alexandros; 348G Foster Drive, Willimantic, CT 06226 (US). KHANOLKAR, Atmaram; No. 55, 1 South Eagleville Road, Storrs, CT 06268 (US). LU, Dai; No. 16, 1 South Eagleville Road, Storrs, CT 06268 (US). (74) Agents: CARROLL, Alice, O. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 3 February 2000 (03.02.00)
(54) Title: CANNABINOIDS SELECTIVE FOR THE CB2 RECEPTOR (57) Abstract Disclosed are novel cannabinoids which are selective for the CB2 receptor. The novel cannabinoids comprise a substituted or unsubstituted tricyclic cannabinoid core and a substituted or unsubstituted C5-C8 carbocyclic ring, five to eight-membered heterocyclic ring or a seven to ten membered bicyclic ring system fused to the monohydroxylated phenyl ring of the cannabinoid core. Also disclosed are methods of suppressing the immune system in a subject by administering to the subject a (e.g. immunosuppressive amount) effective amount of a novel cannabinoid described above.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/09806

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D311/80 C07D311/92 A61K31/35

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	C. G. PITT ET AL.: JOURNAL OF LABELLED COMPOUNDS, vol. 11, no. 4, 1975, pages 551-75, XP002123229 page 557, compound 6; page 561, last paragraph to page 562, line 2	1, 13
P, X	J. W. HUFFMAN ET AL.: BIOORGANIC & MEDICINAL CHEMISTRY, vol. 6, no. 12, 1998, pages 2281-8, XP002123230 page 2281, abstract; compounds 1 and 2; page 2282, compound 6; page 2283, compound 20; page 2284, paragraph "Discussion"	1-4, 13
A	EP 0 276 732 A (F. HOFFMANN-LA ROCHE & CO. AG) 3 August 1988 (1988-08-03) page 2, line 18 - line 37	1, 2, 13
-/-		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

19 November 1999

Date of mailing of the international search report

03/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/09806

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>FR 2 735 774 A (SANOFI S. A.) 27 December 1996 (1996-12-27) claims 1,2</p>	1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/09806

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 7-12 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition (Rule 39.1(iv) PCT-Method for treatment of the human or animal body by therapy).
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 99/09806

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 276732 A	03-08-1988	US 4833073 A	23-05-1989
		AT 97895 T	15-12-1993
		AU 614733 B	12-09-1991
		AU 1111588 A	28-07-1988
		DE 3885911 D	13-01-1994
		DE 3885911 T	24-03-1994
		DK 37888 A	28-07-1988
		ES 2060610 T	01-12-1994
		FI 880332 A,B,	28-07-1988
		HK 63595 A	05-05-1995
		JP 2105912 C	06-11-1996
		JP 8019117 B	28-02-1996
		JP 63192770 A	10-08-1988
		NO 880330 A	28-07-1988
		NZ 223289 A	28-06-1989
		US 5219747 A	15-06-1993
FR 2735774 A	27-12-1996	AU 6363296 A	22-01-1997
		BR 9608640 A	18-05-1999
		CA 2225379 A	09-01-1997
		CN 1192732 A	09-09-1998
		CZ 9704143 A	15-07-1998
		EP 0833818 A	08-04-1998
		WO 9700860 A	09-01-1997
		JP 11507937 T	13-07-1999
		NO 975989 A	19-02-1998
		PL 324185 A	11-05-1998
		SK 173597 A	04-11-1998

